TET2 sirna

TET2 siRNA (Mouse)

Cat. Num. AAA8202260

• Gene Names: Tet2; Ayu17-449; mKIAA1546; E130014J05Rik
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: TET2; TET2 siRNA (Mouse); KIAA1546; Methylcytosine dioxygenase TET2; Protein Ayu17-449; TET2 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: TET2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1912

• Applicable Applications for TET2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse TET2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for TET2 sirna

siRNA to inhibit TET2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 157057152
• NCBI GeneID: 214133
• NCBI Accession #: NP_001035490.2
• NCBI GenBank Nucleotide #: NM_001040400.2
• UniProt Accession #: Q4JK59; Q3U5R5; Q3U633; Q3UAI0; Q6ZPN2; Q8K2K3
• Molecular Weight: 64,499 Da
• NCBI Official Full Name: methylcytosine dioxygenase TET2
• NCBI Official Synonym Full Names: tet methylcytosine dioxygenase 2
• NCBI Official Symbol: Tet2
• NCBI Official Synonym Symbols: Ayu17-449; mKIAA1546; E130014J05Rik
• NCBI Protein Information: methylcytosine dioxygenase TET2
• UniProt Protein Name: Methylcytosine dioxygenase TET2
• Protein Family: Tetraspanin
• UniProt Gene Name: Tet2
• UniProt Synonym Gene Names: Kiaa1546
• UniProt Entry Name: TET2_MOUSE

Uniprot Description

TET2: Catalyzes the conversion of methylcytosine (5mC) to 5- hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Defects in TET2 are a cause of polycythemia vera (PV). A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen. Defects in TET2 are a cause of myelodysplastic syndrome (MDS). A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Belongs to the TET family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Tumor suppressor; EC 1.14.11.n2; Oxidoreductase

Cellular Component: nucleus

Molecular Function: DNA binding; zinc ion binding; dioxygenase activity; ferrous iron binding; metal ion binding; oxidoreductase activity

Biological Process: spleen development; protein amino acid O-linked glycosylation; hemoglobin metabolic process; homeostasis of number of cells; chromatin modification; 5-methylcytosine metabolic process; cell cycle; post-embryonic development; myeloid progenitor cell differentiation; cytosine metabolic process; 5-methylcytosine catabolic process; myeloid cell differentiation; hemopoiesis; positive regulation of transcription from RNA polymerase II promoter; kidney development